IT1312086B1 - Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress - Google Patents

Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress

Info

Publication number
IT1312086B1
IT1312086B1 IT1999MI000831A ITMI990831A IT1312086B1 IT 1312086 B1 IT1312086 B1 IT 1312086B1 IT 1999MI000831 A IT1999MI000831 A IT 1999MI000831A IT MI990831 A ITMI990831 A IT MI990831A IT 1312086 B1 IT1312086 B1 IT 1312086B1
Authority
IT
Italy
Prior art keywords
nac
preparation
intravenous administration
drug suitable
stress prevention
Prior art date
Application number
IT1999MI000831A
Other languages
English (en)
Inventor
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IT1999MI000831A priority Critical patent/IT1312086B1/it
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to JP2000613412A priority patent/JP2002542279A/ja
Priority to PCT/EP2000/003485 priority patent/WO2000064421A2/en
Priority to BR0009875-2A priority patent/BR0009875A/pt
Priority to HU0200861A priority patent/HU227537B1/hu
Priority to NZ514911A priority patent/NZ514911A/xx
Priority to US09/926,363 priority patent/US6627659B1/en
Priority to EP00925220A priority patent/EP1171112A2/en
Priority to IL14603200A priority patent/IL146032A0/xx
Priority to CA002369942A priority patent/CA2369942A1/en
Priority to AU44012/00A priority patent/AU771390B2/en
Publication of ITMI990831A1 publication Critical patent/ITMI990831A1/it
Priority to IL146032A priority patent/IL146032A/en
Application granted granted Critical
Publication of IT1312086B1 publication Critical patent/IT1312086B1/it
Priority to US10/354,076 priority patent/US20030139472A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
IT1999MI000831A 1999-04-21 1999-04-21 Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress IT1312086B1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT1999MI000831A IT1312086B1 (it) 1999-04-21 1999-04-21 Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
IL14603200A IL146032A0 (en) 1999-04-21 2000-04-18 Use of n-acetylcysteine for the preparation of a medicament suitable for intravenous administration to prevent oxidative stress in dialysed patients
BR0009875-2A BR0009875A (pt) 1999-04-21 2000-04-18 Uso de n-acetilcisteìna para a preparação de um medicamento adequado para a administração intravenosa para prevenir a carga oxidativa em pacientes que sofreram diálise
HU0200861A HU227537B1 (en) 1999-04-21 2000-04-18 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
NZ514911A NZ514911A (en) 1999-04-21 2000-04-18 Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
US09/926,363 US6627659B1 (en) 1999-04-21 2000-04-18 Methods of decreasing the effects of oxidative stress using N-acetylcysteine
JP2000613412A JP2002542279A (ja) 1999-04-21 2000-04-18 透析患者における酸化的ストレスを防止するための静脈投与に適した医薬の製造へのｎ−アセチルシステインの使用
PCT/EP2000/003485 WO2000064421A2 (en) 1999-04-21 2000-04-18 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
CA002369942A CA2369942A1 (en) 1999-04-21 2000-04-18 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
AU44012/00A AU771390B2 (en) 1999-04-21 2000-04-18 Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
EP00925220A EP1171112A2 (en) 1999-04-21 2000-04-18 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
IL146032A IL146032A (en) 1999-04-21 2001-10-18 Use of N-acetylcysteine for the preparation of appropriate intravenous drugs to prevent oxidative stress in dialysis patients
US10/354,076 US20030139472A1 (en) 1999-04-21 2003-01-30 Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI000831A IT1312086B1 (it) 1999-04-21 1999-04-21 Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress

Publications (2)

Publication Number Publication Date
ITMI990831A1 ITMI990831A1 (it) 2000-10-21
IT1312086B1 true IT1312086B1 (it) 2002-04-04

Family

ID=11382781

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI000831A IT1312086B1 (it) 1999-04-21 1999-04-21 Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress

Country Status (11)

Country Link
US (2) US6627659B1 (it)
EP (1) EP1171112A2 (it)
JP (1) JP2002542279A (it)
AU (1) AU771390B2 (it)
BR (1) BR0009875A (it)
CA (1) CA2369942A1 (it)
HU (1) HU227537B1 (it)
IL (2) IL146032A0 (it)
IT (1) IT1312086B1 (it)
NZ (1) NZ514911A (it)
WO (1) WO2000064421A2 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20070232422A1 (en) * 2006-03-30 2007-10-04 Jung-Shih Chang Baseball bat with a break resistant structure
BG66222B1 (bg) * 2006-06-08 2012-06-29 "Унифарм" Ад Диализен състав
ATE489950T1 (de) * 2006-06-22 2010-12-15 Gambro Lundia Ab Lösung enthaltend n-acetylcystein und gluconsäure,und verfahren zur verringerung, behandlung und/oder verhinderung von oxidativem stress und zellaktivierung
CN102526237B (zh) * 2012-01-21 2014-06-25 南方医科大学南方医院 用于清除晚期氧化蛋白终产物的药物组合物及其用途
US10705093B2 (en) 2014-07-25 2020-07-07 Bloodworks Determination of small-molecule thiols and disulfides: protein bound cys and total cysteine as biomarkers of oxidative stress
IT201900002919A1 (it) * 2019-02-28 2020-08-28 Solongevity Nutraceuticals S R L Composizione antiossidante

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216506D0 (en) * 1992-08-04 1992-09-16 Rice Evans Catherine A Improvements in or relating to the treatment of sickle cell disease
AU5726796A (en) 1995-05-05 1996-11-21 Ameritool Corporation Electrically operated material dispensing gun and method
ES2114817B1 (es) * 1996-05-16 1999-02-16 Zambon S A Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury

Also Published As

Publication number Publication date
AU771390B2 (en) 2004-03-18
JP2002542279A (ja) 2002-12-10
WO2000064421A2 (en) 2000-11-02
HUP0200861A2 (hu) 2002-07-29
HUP0200861A3 (en) 2003-04-28
HU227537B1 (en) 2011-08-29
ITMI990831A1 (it) 2000-10-21
BR0009875A (pt) 2002-04-09
US6627659B1 (en) 2003-09-30
CA2369942A1 (en) 2000-11-02
IL146032A (en) 2007-05-15
AU4401200A (en) 2000-11-10
NZ514911A (en) 2004-03-26
EP1171112A2 (en) 2002-01-16
WO2000064421A3 (en) 2001-10-11
US20030139472A1 (en) 2003-07-24
IL146032A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
PT1221918E (pt) Administracao de drogas sub-tenon
DK1207867T3 (da) Retarderede, orale farmaceutiske indgivelsesformer med tramadol
EE05123B1 (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
ATE312602T1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
DK0864327T3 (da) Anvendelse af pyrimidinderivater til fremstilling af et lægemiddel til forebyggelse af kræft
BR9708706B1 (pt) composiÇço farmacÊutica para administraÇço intravenosa a um paciente
ATE432707T1 (de) Pharmazeutische zubereitung
PT1165081E (pt) Processo para a preparacao de preparacoes farmaceuticas cintendo tolperisona, para administracao oral
IT1312086B1 (it) Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
NO20031958L (no) Farmasöytisk dronedaron-preparat for parenteral administrering
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
NO992999D0 (no) Farmas°ytisk blanding for oral administrering
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
EP1044691A3 (en) Use of glycosaminoglycan lipid conjugates for inducing osteogenesis
DE19681529D2 (de) Pharmazeutische Darreichungsform
ITMI20011237A0 (it) Uso della yohimbina per la preparazione di farmaci ad attivita' immunobiologica
ITMI20011628A1 (it) Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per il trattamento del fenomeno di
ITRM20010293A0 (it) Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
ITMI982246A0 (it) Uso di androst-5-ene-3beta,7beta-17beta-triolo per la preparazione di un medicamento utile per il trattamento dello stress cronico
IT1302858B1 (it) Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale.
IT1295067B1 (it) Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale
NO20003284D0 (no) Farmasøytisk preparat for oral administrering